Email this article Therapy of lymphoproliferative diseases in the era of COVID-19: challenges and solutions
- Authors: Poddubnaya I.V.1,2
-
Affiliations:
- Journal "Modern Oncology"
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 24, No 1 (2022)
- Pages: 67-72
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/106864
- DOI: https://doi.org/10.26442/18151434.2022.1.201441
- ID: 106864
Cite item
Full Text
Abstract
On January 20,2022, the symposium "Therapy of lymphoproliferative diseases in the era of COVID-19: difficulties and solutions" was held. It was organized by the Russian Society of Oncohematologists. At the symposium, the experience of the hematology service of City Clinical Hospital №52 of Moscow was discussed, as well as changes in international clinical guidelines for managing patients in conditions of COVID-19 based on a review conducted by the European Hematology Association (EPICOVIDEHA).
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Irina V. Poddubnaya
Journal "Modern Oncology"; Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: editor@consiliummedicum.ru
Editor-in-Chief, Academician of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor
Russian Federation, Moscow; MoscowSupplementary files
